Ask AI
ProCE Banner Activity

Novel Targeted Therapies for PIK3CA/AKT1/PTEN-Altered Metastatic Breast Cancer: Key Evidence and Real-world Insights to Optimize Patient Care

Clinical Thought

Read this commentary with expert insights on available and emerging data for PI3K/AKT inhibitors in patients with HR-positive/HER2-negative metastatic breast cancer and a PIK3CA/AKT/PTEN gene alterations including assessing evaluable patients eligible for therapy based on recent approved indications and overcoming clinical barriers to adoption.

Released: September 29, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd.

Disclosure

Primary Author

Nadia Harbeck, MD, PhD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Viatris.